查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1808925

病毒载体合约开发製造组织市场，按载体类型、按工作流程阶段、按规模、按应用、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Viral Vector Contract Development Manufacturing Organizations Market, By Vector Type, By Workflow Stage, By Scale, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 378 Pages | 商品交期: 2-3个工作天内

价格
简介目录

病毒载体合约开发製造组织市场规模在 2024 年价值 11.23 亿美元，从 2025 年到 2032 年的复合年增长率为 18.5%。

病毒载体合约开发与製造组织 (CDMO) 市场专注于为基因疗法、疫苗和细胞疗法中使用的病毒载体生产提供外包服务。到 2024 年中期，全球将有超过 30 个基因疗法获批，并且腺相关病毒 (AAV)、慢病毒和腺病毒载体试验的管道不断扩大，这正在推动对专业化生产的需求。製药和生物技术公司不断增加的投资正在推动 CDMO 扩张，例如赛默飞世尔科技 (Thermo Fisher Scientific) 将在 2023 年投资 6.5 亿美元，以扩展其细胞和基因治疗网络。然而，高昂的生产成本、复杂的生物加工以及对病毒安全性和一致性的监管审查可能会阻碍其发展。儘管如此，透过战略合作伙伴关係、平台标准化以及缺乏国内载体生产的地区不断增长的需求，机会正在涌现。

病毒载体合约开发製造组织市场-市场动态

基因治疗产品线的拓展和生物技术投资加速病毒载体CDMO市场的成长

基因治疗产品线的快速扩张和生物技术投资的增加正在加速病毒载体CDMO市场的成长。根据美国FDA和再生医学联盟的数据，截至2024年，全球有超过2,000项基因治疗临床试验正在进行中。这种激增促使主要製药公司将载体生产外包给专门的CDMO，以满足可扩展性和合规性需求。 2023年，美国生物医学高级研究与发展管理局（BARDA）拨款扩大国内病毒载体生产，以减少对海外供应的依赖。 Catalent和赛默​​飞世尔科技等公司已投资数亿美元用于增强病毒载体基础设施，以满足肿瘤学和罕见疾病治疗对AAV和慢病毒载体日益增长的需求。这些发展突显了在北美和欧洲建立长期CDMO合作伙伴关係和策略性产能扩张的明显趋势。

病毒载体合约开发製造组织市场-关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 18.5%。

根据载体类型细分，预计腺相关病毒 (AAV) 将在 2024 年占据最大市场份额

根据工作流程阶段细分，上游处理是 2024 年领先的工作流程阶段

根据量表细分，临床量表是2024年领先的量表

按地区划分，北美是 2024 年的主要收入来源

病毒载体合约开发製造组织市场区隔分析：

全球病毒载体合约开发製造组织市场根据载体类型、工作流程阶段、规模、应用和地区进行细分。

根据载体类型，市场分为六类：腺病毒、慢病毒、腺相关病毒、逆转录病毒、单纯疱疹病毒、杂交/嵌合载体。腺相关病毒 (AAV) 因其在基因传递方面的安全性和效率而处于领先地位，其次是慢病毒，因其稳定的基因整合能力而占据主导地位。腺病毒在疫苗开发中排名第三，而逆转录病毒、单纯疱疹病毒和杂交载体则用于利基疗法。

根据工作流程阶段，市场可分为两类：上游处理（细胞培养（HEK293、Sf9）、转染/感染方案）和下游处理（过滤和层析、超速离心、最终产品製剂）。上游处理占据优先地位，其中HEK293细胞培养和优化的转染方案广泛用于可扩展的载体生产。其次是下游处理，其中过滤和层析主要用于纯化，而超速离心和最终製剂对于确保载体稳定性和临床级品质至关重要。

病毒载体合约开发製造组织市场-地理洞察

北美在病毒载体CDMO市场占据领先地位，得益于其强大的生物製药生态系统、政府资金和先进的基础设施。 2023年，赛默飞世尔科技扩建了位于马里兰州的工厂，以提高AAV载体的生产能力，同时美国FDA继续加速基因疗法的批准。欧洲也是一个重要的枢纽，德国、英国和荷兰对合约生产的需求不断增长。 2024年6月，Catalent与Oxford Biomedica合作，为欧洲客户扩大病毒载体的生产规模。同时，以中国、日本和韩国为首的亚太地区正快速崛起，这些地区政府对细胞和基因治疗的支持力度不断加大，促使当地CDMO提升产能。 2024年，日本AGC Biologics宣布与当地基因治疗公司建立策略伙伴关係，在千叶建立病毒载体生产线，标誌着该地区产能的增强。

病毒载体合约开发製造组织市场-竞争格局：

病毒载体CDMO市场呈现领导企业策略布局与产能扩张的态势。赛默飞世尔科技（Thermo Fisher Scientific）引领市场，于2019年收购了Brammer Bio，并于2021年1月以约7.25亿欧元（约合8.75亿美元）收购了诺华赛普（Novasep）旗下的Henogen部门，显着增强了其在欧洲的病毒载体和剑桥业务。 Catalent在过去十年中支持了超过一半的FDA批准新药，并在50多家工厂每年生产约700亿剂药物。诺和诺德（Novo Holdings）于2024年12月以165亿美元收购了Catalent，重塑了药物、基因治疗和注射给药领域的合约生产格局。区域合作进一步加剧了竞争，例如Catalent与Sarepta Therapeutics以及多家新冠疫苗製造商的合作。这些併购和联盟策略共同展现了其透过规模化、全球覆盖和治疗专业化来增强差异化的优势。

最新动态：

2025年6月，ProBio在新泽西州霍普韦尔开设了一座占地12.8万平方英尺的GMP工厂，用于生产质粒DNA和病毒载体。该厂将于2025年第三季开始生产AAV，并于2026年第一季开始提供LVV服务。

2024 年 5 月，Charles River Laboratories 启动了一项病毒载体技术转移计划，提供两个框架——用于无缝转移的快速通道和用于可定制应用的模组化——以便在短短 9 个月内加速向其马里兰卓越中心的流程交接。

2024年9月，Rentschler Biopharma在其位于英国史蒂夫尼奇的先进疗法工厂推出了一套全面的慢病毒载体 (LVV) 生产工具箱，以补充其现有的AAV服务。这套工具箱包括製程开发、cGMP 生产以及免版税的 HEK293细胞株，以加速 ATMP 的生产。

目录

第一章：病毒载体合约开发製造组织市场概览

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 病毒载体合约开发製造组织市场片段（按载体类型）
    • 病毒载体合约开发製造组织市场片段（依工作流程阶段）
    • 病毒载体合约开发製造组织市场片段（按规模）
    • 病毒载体合约开发製造组织市场片段（按应用）
    • 病毒载体合约开发製造组织市场片段（按国家/地区）
    • 病毒载体合约开发製造组织市场片段（按地区）
  • 竞争洞察

第三章：病毒载体合约开发製造组织关键市场趋势

  • 病毒载体合约开发製造组织市场驱动因素
    • 市场驱动因素的影响分析
  • 病毒载体合约开发製造组织市场限制
    • 市场限制的影响分析
  • 病毒载体合约开发製造组织市场机会
  • 病毒载体合约开发製造组织市场未来趋势

第四章：病毒载体合约开发製造组织产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：病毒载体合约开发製造组织市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：病毒载体合约开发製造组织市场格局

  • 病毒载体合约开发製造组织市场占有率分析（2024年）
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：病毒载体合约开发製造组织市场 - 按载体类型

  • 概述
    • 按向量类型进行细分份额分析
    • 腺病毒
    • 慢病毒
    • 腺相关病毒
    • 逆转录病毒
    • 单纯疱疹病毒
    • 杂交/嵌合载体

第八章：病毒载体合约开发製造组织市场－依工作流程阶段

  • 概述
    • 依工作流程阶段进行细分份额分析
    • 上游处理
      • 细胞培养（HEK293、Sf9）
      • 转染/感染方案
    • 下游加工
      • 过滤和色谱法
      • 超速离心
      • 最终产品配方

第九章：病毒载体合约开发製造组织市场—依规模

  • 概述
    • 按规模细分市场占有率分析
    • 临床前（研发批次）
    • 临床（I-III期）
    • 商业（市场供应）

第十章：病毒载体合约开发製造组织市场-按应用

  • 概述
    • 按应用细分市场占有率分析
    • 基因治疗
    • 癌症免疫疗法
    • 传染病疫苗
    • 罕见疾病治疗

第 11 章：病毒载体合约开发製造组织市场-按地域

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 病毒载体合约开发製造组织北美主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按向量类型）
    • 北美市场规模与预测（按工作流程阶段）
    • 北美市场规模及预测（按规模）
    • 北美市场规模和预测（按应用）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 病毒载体合约开发製造组织欧洲主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模和预测（按向量类型）
    • 欧洲市场规模与预测（按工作流程阶段）
    • 欧洲市场规模及预测（按规模）
    • 欧洲市场规模和预测，按应用
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 病毒载体合约开发製造组织亚太地区主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依载体类型）
    • 亚太地区市场规模及预测（依工作流程阶段）
    • 亚太地区市场规模及预测（依规模）
    • 亚太地区市场规模及预测（按应用）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 病毒载体合约开发製造组织拉丁美洲主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依向量类型）
    • 拉丁美洲市场规模及预测（依工作流程阶段）
    • 拉丁美洲市场规模及预测（按规模）
    • 拉丁美洲市场规模及预测（按应用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 病毒载体合约开发製造组织中东和非洲的主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依载体类型）
    • MEA 市场规模与预测（依工作流程阶段）
    • MEA 市场规模及预测（按规模）
    • MEA 市场规模及预测（按应用）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：关键供应商分析-病毒载体合约开发製造组织产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • AGC Biologics
    • Aldevron
    • Batavia Biosciences
    • BioReliance (Merck KGaA)
    • Catalent
    • Charles River Laboratories
    • Cobra Biologics (Charles River)
    • FUJIFILM Diosynth Biotechnologies
    • Genezen
    • iBET
    • Kaneka Eurogentec
    • Lonza
    • Novasep
    • Oxford Biomedica
    • REGENXBIO (CDMO Services arm)
    • Thermo Fisher Scientific (Patheon)
    • Vigene Biosciences (Charles River)
    • VIVEbiotech
    • WuXi Advanced Therapies
    • Yposkesi
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5543

Viral Vector Contract Development Manufacturing Organizations Market size was valued at US$ 1,123 Million in 2024, expanding at a CAGR of 18.5% from 2025 to 2032.

The Viral Vector Contract Development and Manufacturing Organizations (CDMO) Market focuses on outsourcing services for the production of viral vectors used in gene therapies, vaccines, and cell-based treatments. Over 30 gene therapy approvals globally by mid-2024 and an expanding pipeline of AAV, lentiviral, and adenoviral vector trials are fueling demand for specialized manufacturing. Rising investments from pharma and biotech firms are pushing CDMOs to scale up, with Thermo Fisher Scientific investing $650 million in 2023 to expand its cell and gene therapy network. However, high production costs, complex bioprocessing, and regulatory scrutiny over viral safety and consistency may restrain progress. Nonetheless, opportunities are emerging through strategic partnerships, platform standardization, and rising demand from regions lacking domestic vector production.

Viral Vector Contract Development Manufacturing Organizations Market- Market Dynamics

Expanding Gene Therapy Pipeline and Biotech Investments Accelerate Growth of Viral Vector CDMO Market

The rapid expansion of gene therapy pipelines and increased biotech investments are accelerating the growth of the viral vector CDMO market. As of 2024, over 2,000 gene therapy clinical trials are active globally, according to the U.S. FDA and Alliance for Regenerative Medicine. This surge has prompted major pharmaceutical players to outsource vector production to specialized CDMOs to meet scalability and compliance needs. In 2023, the U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded funding to expand domestic viral vector manufacturing to reduce reliance on overseas supply. Companies like Catalent and Thermo Fisher Scientific have invested hundreds of millions to enhance viral vector infrastructure, addressing the rising demand for AAV and lentiviral vectors in oncology and rare disease therapies. These developments underscore a clear trend toward long-term CDMO partnerships and strategic capacity expansion across North America and Europe.

Viral Vector Contract Development Manufacturing Organizations Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 18.5% over the forecast period (2025-2032)

Based on Vector Type segmentation, Adeno-associated virus (AAV) was predicted to show maximum market share in the year 2024

Based on Workflow Stage segmentation, Upstream processing was the leading Workflow Stage in 2024

Based on Scale segmentation, the Clinical scale was the leading Scale in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Contract Development Manufacturing Organizations Market- Segmentation Analysis:

The Global Viral Vector Contract Development Manufacturing Organizations Market is segmented on the basis of Vector Type, Workflow Stage, Scale, Application, and Region.

The market is divided into six categories based on Vector Type: Adenovirus, Lentivirus, Adeno-associated Virus, Retrovirus, Herpes Simplex Virus, and Hybrid/Chimeric Vectors. Adeno-associated virus (AAV) leads due to its proven safety and efficiency in gene delivery, followed by lentivirus for stable gene integration. Adenovirus ranks third for vaccine development, while retrovirus, herpes simplex virus, and hybrid vectors are used in niche therapies.

The market is divided into two categories based on Workflow Stage: Upstream Processing (Cell culture (HEK293, Sf9), Transfection/infection protocols), and Downstream Processing (Filtration & Chromatography, Ultracentrifugation, Final Product Formulation). Upstream processing holds priority, with HEK293 cell culture and optimized transfection protocols widely used for scalable vector production. Downstream processing follows, where filtration and chromatography dominate purification, while ultracentrifugation and final formulation are essential for ensuring vector stability and clinical-grade quality.

Viral Vector Contract Development Manufacturing Organizations Market- Geographical Insights

North America holds a leading position in the viral vector CDMO market, supported by a robust biopharma ecosystem, government funding, and advanced infrastructure. In 2023, Thermo Fisher Scientific expanded its Maryland facility to enhance AAV vector production, while the U.S. FDA continued to accelerate approvals for gene therapies. Europe is also a key hub, with growing demand for contract manufacturing in Germany, the UK, and the Netherlands. In June 2024, Catalent collaborated with Oxford Biomedica to scale up viral vector manufacturing for European clients. Meanwhile, the Asia-Pacific region is emerging rapidly, led by China, Japan, and South Korea, where increasing government support for cell and gene therapy is prompting local CDMOs to boost capabilities. In 2024, Japan's AGC Biologics announced a strategic partnership with a local gene therapy company to establish viral vector production lines in Chiba, signaling regional capacity strengthening.

Viral Vector Contract Development Manufacturing Organizations Market- Competitive Landscape:

The viral vector CDMO market features strategic moves and capacity expansion among top players. Thermo Fisher Scientific leads the charge, acquiring Brammer Bio in 2019 and Novasep's Henogen division in January 2021 for approximatel €725 million (~$875 million), significantly enhancing its European viral vector footprint and complementing U.S. operations in Lexington, Cambridge, Plainville, and Alachua. Catalent-supporting over half of FDA-approved new drugs in the past decade and producing roughly 70 billion doses annually across 50+ facilities-was acquired by Novo Holdings for $16.5 billion in December 2024, reshaping contract manufacturing dynamics across drug, gene therapy, and injection delivery segments. Regional collaborations further enrich competition, such as Catalent's partnerships with Sarepta Therapeutics and multiple COVID-19 vaccine manufacturers. Together, these M&A and alliance strategies demonstrate intensifying differentiation through scale, global coverage, and therapeutic specialization.

Recent Developments:

In June 2025, ProBio opened a 128,000 sq ft GMP facility in Hopewell, New Jersey, to produce plasmid DNA and viral vectors. The site will begin AAV manufacturing by Q3 2025 and LVV services by Q1 2026.

In May 2024, Charles River Laboratories launched a viral vector tech transfer program, offering two frameworks-Fast Track for seamless transfers and Modular for customizable applications-to accelerate process handoffs to its Maryland Center of Excellence in as little as nine months.

In September 2024, Rentschler Biopharma launched a comprehensive lentiviral vector (LVV) manufacturing toolbox at its advanced therapies facility in Stevenage, UK, complementing its existing AAV services. This includes process development, cGMP manufacturing, and a royalty-free HEK293 cell line to accelerate ATMP production.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AGC Biologics
  • Aldevron
  • Batavia Biosciences
  • BioReliance (Merck KGaA)
  • Catalent
  • Charles River Laboratories
  • Cobra Biologics (Charles River)
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • iBET
  • Kaneka Eurogentec
  • Lonza
  • Novasep
  • Oxford Biomedica
  • REGENXBIO (CDMO Services arm)
  • Thermo Fisher Scientific (Patheon)
  • Vigene Biosciences (Charles River)
  • VIVEbiotech
  • WuXi Advanced Therapies
  • Yposkesi
  • Others

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Lentivirus
  • Adeno-associated Virus
  • Retrovirus
  • Herpes Simplex Virus
  • Hybrid/Chimeric Vectors

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY WORKFLOW STAGE- MARKET ANALYSIS, 2019 - 2032

  • Upstream Processing
  • Cell culture (HEK293, Sf9)
  • Transfection/infection protocols
  • Downstream Processing
  • Filtration & Chromatography
  • Ultracentrifugation
  • Final Product Formulation

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY SCALE- MARKET ANALYSIS, 2019 - 2032

  • Preclinical (R&D batches)
  • Clinical (Phase I-III)
  • Commercial (Market-ready supply)

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Gene Therapy
  • Cancer Immunotherapy
  • Infectious Disease Vaccines
  • Rare Disease Treatment

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector Contract Development Manufacturing Organizations Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Vector Type
    • 2.1.2. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Workflow Stage
    • 2.1.3. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Scale
    • 2.1.4. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Application
    • 2.1.5. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Country
    • 2.1.6. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector Contract Development Manufacturing Organizations Key Market Trends

  • 3.1. Viral Vector Contract Development Manufacturing Organizations Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector Contract Development Manufacturing Organizations Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector Contract Development Manufacturing Organizations Market Opportunities
  • 3.4. Viral Vector Contract Development Manufacturing Organizations Market Future Trends

4. Viral Vector Contract Development Manufacturing Organizations Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector Contract Development Manufacturing Organizations Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Viral Vector Contract Development Manufacturing Organizations Market Landscape

  • 6.1. Viral Vector Contract Development Manufacturing Organizations Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector Contract Development Manufacturing Organizations Market - By Vector Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vector Type, 2024 & 2032 (%)
    • 7.1.2. Adenovirus
    • 7.1.3. Lentivirus
    • 7.1.4. Adeno-associated Virus
    • 7.1.5. Retrovirus
    • 7.1.6. Herpes Simplex Virus
    • 7.1.7. Hybrid/Chimeric Vectors

8. Viral Vector Contract Development Manufacturing Organizations Market - By Workflow Stage

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Workflow Stage, 2024 & 2032 (%)
    • 8.1.2. Upstream Processing
      • 8.1.2.1. Cell culture (HEK293, Sf9)
      • 8.1.2.2. Transfection/infection protocols
    • 8.1.3. Downstream Processing
      • 8.1.3.1. Filtration & Chromatography
      • 8.1.3.2. Ultracentrifugation
      • 8.1.3.3. Final Product Formulation

9. Viral Vector Contract Development Manufacturing Organizations Market - By Scale

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Scale, 2024 & 2032 (%)
    • 9.1.2. Preclinical (R&D batches)
    • 9.1.3. Clinical (Phase I-III)
    • 9.1.4. Commercial (Market-ready supply)

10. Viral Vector Contract Development Manufacturing Organizations Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Gene Therapy
    • 10.1.3. Cancer Immunotherapy
    • 10.1.4. Infectious Disease Vaccines
    • 10.1.5. Rare Disease Treatment

11. Viral Vector Contract Development Manufacturing Organizations Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Viral Vector Contract Development Manufacturing Organizations Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AGC Biologics
    • 12.2.2. Aldevron
    • 12.2.3. Batavia Biosciences
    • 12.2.4. BioReliance (Merck KGaA)
    • 12.2.5. Catalent
    • 12.2.6. Charles River Laboratories
    • 12.2.7. Cobra Biologics (Charles River)
    • 12.2.8. FUJIFILM Diosynth Biotechnologies
    • 12.2.9. Genezen
    • 12.2.10. iBET
    • 12.2.11. Kaneka Eurogentec
    • 12.2.12. Lonza
    • 12.2.13. Novasep
    • 12.2.14. Oxford Biomedica
    • 12.2.15. REGENXBIO (CDMO Services arm)
    • 12.2.16. Thermo Fisher Scientific (Patheon)
    • 12.2.17. Vigene Biosciences (Charles River)
    • 12.2.18. VIVEbiotech
    • 12.2.19. WuXi Advanced Therapies
    • 12.2.20. Yposkesi
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us